Healthcare Stocks Trading Mixed: OPK, SNTS, EXEL, NKTR, ACHN

Houston, TX -- (SBWIRE) -- 01/18/2013 -- AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.

Opko Health Inc. (NYSE:OPK) added 1.17% and is trading at $6.07. OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company that develops solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions.

Can OPK Rebound After The Recent Slump and Investors Can Make Money? Find Out Here

Santarus, Inc. (NASDAQ:SNTS) is higher 2.61% and is trading at $12.59. Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2011, the Company’s marketed and approved products included Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets, Fenoglide (fenofibrate) tablets, and Zegerid (omeprazole/sodium bicarbonate) capsules and powder for oral suspension.

How Should Investors Trade SNTS After The Recent Volatile Moves? Find Out Here

Exelixis, Inc. (NASDAQ:EXEL) is lower 0.97% and is trading at $4.59. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.

Is EXEL Showing Any Sign of Buy At The Current Market Price? Get Our Free Trend Analysis Here

Nektar Therapeutics (NASDAQ:NKTR) fell 1.13% and is trading at $8.77. Provides a portfolio of drug delivery technologies to assist pharmaceutical and biotechnology companies with the development of their drug products, drug delivery, product franchises, and product pipelines. The Company offers drug delivery technologies that includes molecule engineering, particle engineering, and drug delivery solutions for both large and small molecules.

Can NKTR Rebound After The Recent Slump and Investors Can Make Money? Find Out Here

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is lower 1.96% and is trading at $9.02. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections.

Is ACHN Ready To Move Back To New Highs This Year? Find Out Here

Disclaimer
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information:
Winning Media LLC
1-800-411-7716
ir@AnotherWinningTrade.com